Vial

DECEMBER 11, 2023

Pathophysiological evidence links HCV infections to the risk of liver diseases such as hepatocellular carcinoma (HCC) and liver cirrhosis. Despite advances in clinical research, there remain significant challenges as only 20% of HCV cases are diagnosed, and of these, only 15% receive treatment.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

Conversations in Drug Development Trends

JULY 9, 2024

Our metabolic team is actively involved in advancing clinical trials that explore GLP-1’s potential to reduce liver fat, mitigate inflammation, and ultimately improve outcomes for patients at risk of liver disease progression.

Clinical Research 52

Clinical Research Treatment Research Clinical Trials 52

Drug Target Review

MAY 7, 2024

Why are biomarkers particularly critical in the context of rare diseases? Developing novel therapeutic approaches for rare diseases poses inherent challenges due to the limited populations available for testing. How do AI-enhanced approaches accelerate the drug development process for rare diseases?

Disease 59

Disease Clinical Trials Clinical Pharmacology Trials 59

PPD

JANUARY 5, 2023

In an industry survey led by PPD, Thermo Fisher Scientific’s clinical research business, rare diseases emerged as a top therapeutic area in drug developers’ pipelines, with 39% of global biotech and biopharma leaders pursuing therapies in the broad rare disease space.

Disease 52

Disease Trials Clinical Trials Clinical Research 52

PPD

OCTOBER 17, 2024

This expansion represents a significant opportunity for both drug developers and patients, while also presenting a new and diverse set of challenges for drug developers, particularly in clinical trial execution.

Therapies 52

Therapies Clinical Trials Clinical Research Trials 52

Drug Target Review

SEPTEMBER 5, 2024

However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company. What potential future applications or implications do you foresee based on your work?

Pharma Companies 112

Pharma Companies Licensing Licensing Disease 112

Labcorp Drug Development

MARCH 7, 2023

The field of nephrology clinical research has been steadily adding new interventional trials over the last five years at an average pace of 176 trials per year. This activity reflects the … The post Enabling better access to kidney disease trials appeared first on Insights From Our Labs to Yours.

Trials 52

Trials Disease Clinical Research Research 52

Drug Target Review

OCTOBER 16, 2024

My clinical background as a physician led me to drug development, where I realised I could have an even broader impact on patient well-being. The ability to translate clinical experience into scientific innovation was deeply inspiring to me, because it meant contributing to solutions that could benefit far more patients.

Clinical Development 52

Clinical Development Drug Development Therapies Disease 52

Conversations in Drug Development Trends

OCTOBER 24, 2023

In the US, a rare disease is one with 200,000 or fewer patients. Rare diseases exist in every therapeutic area and are often the more complex indications of each therapeutic area. Although no two rare disease patient communities are identical, there are common themes to the evolutionary arc of PAO maturation.

Clinical Trials 52

Clinical Trials Disease Therapies Drug Development 52

PPD

JUNE 7, 2023

Adults aren’t the only patients affected by the increasing prevalence of liver disease. The number of pediatric patients diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is on the rise, yet there are currently no approved therapies to treat NAFLD and NASH in adult or pediatric populations.

Trials 98

Trials Clinical Trials Clinical Research Disease 98

Conversations in Drug Development Trends

NOVEMBER 3, 2022

BioPharma Dive interviewed our Derek Ansel on how to conduct psychedelic clinical research. In April 2022, the Food and Drug Administration (FDA) issued draft guidance on developing a “Race and Ethnicity Diversity Plan” for clinical trials. Reach out to learn how Worldwide Clinical Trials can help.

Disease 52

Disease Clinical Trials Trials International 52

PPD

MAY 18, 2023

For neurodegenerative disease research, the care partner, or caregiver, is equally important as the person with dementia. Even with stronger awareness of studies, drug developers must contend with the inherent lack of trust between the dementia community and clinical trials. There’s little time to lose.

Clinical Trials 86

Clinical Trials Trials Clinical Research Doctors 86

Conversations in Drug Development Trends

FEBRUARY 26, 2024

With the necessary prioritization of various factors when designing your clinical trial, the patient experience can be overlooked or improperly addressed in study design. However, incorporating the patient experience into your design is one of the best ways to ensure your drug development program is a commercial success.

Clinical Trials 59

Clinical Trials Trials Disease Clinical Research 59

Conversations in Drug Development Trends

FEBRUARY 22, 2023

Rare Disease Day on February 28th is a chance for rare disease communities to come together as one and join in conversation with stakeholders searching for treatments, raising money to support research, and changing the way healthcare and governments interact with patients. In my case, my daughter Iris has GM1 gangliosidosis.

Disease 52

Disease Clinical Trials Trials Treatment 52

PPD

NOVEMBER 30, 2023

As we approach the end of 2023, it’s time to reflect on the past 12 months and how advances in drug development shaped the pharma and biotech industries. These shifts are a prelude to further change and progress in the clinical trial landscape in 2024. Five Predictions for the Drug Development Industry in 2024 1.

Clinical Trials 98

Clinical Trials Trials Clinical Research Drug Development 98

Conversations in Drug Development Trends

OCTOBER 14, 2024

Autoimmune diseases and bone health conditions are not just medical challenges – they’re personal battles that millions of people fight every day. Fortunately, advances in clinical research are providing hope for better treatments and outcomes.

Research 52

Research Clinical Trials Therapies Immune Response 52

Conversations in Drug Development Trends

OCTOBER 14, 2024

Autoimmune diseases and bone health conditions are not just medical challenges – they’re personal battles that millions of people fight every day. Fortunately, advances in clinical research are providing hope for better treatments and outcomes.

Research 52

Research Clinical Trials Therapies Immune Response 52

PPD

JUNE 27, 2024

AA is considered a dermatology autoimmune disease, wherein the body fails to recognize its own cells and leads to subsequent immune-mediated destruction of the hair follicle. In general, ongoing research in AA is focused on molecules whose mechanism of actions and effectiveness have been proven in psoriasis and atopic dermatitis.

Treatment 52

Treatment Clinical Trials Clinical Research Small Molecule 52

Conversations in Drug Development Trends

APRIL 8, 2024

Expertly managed clinical assessments by a team with fastidious attention to detail optimizes precision and reliability and helps you successfully navigate the complex terrain of clinical research. Our cohesive approach, characterized by its agility, precision, and collaborative spirit, transforms our partnerships.

Clinical Trials 75

Clinical Trials Clinical Research Trials Compliance 75

PPD

NOVEMBER 7, 2023

The underrepresentation of diverse groups in clinical research is an area of regulatory, scientific and industry focus, partly due to the recent U.S. Food and Drug Administration (FDA) draft guidance, “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials.”

Clinical Trials 59

Clinical Trials Trials Clinical Research Disease 59

Vial

MARCH 25, 2024

Therapeutic Area Coverage Worldwide Clinical Trials (Worldwide) focuses on the following therapeutic areas: neuroscience, oncology , rare diseases, and cardiometabolic and inflammatory diseases. In common with Worldwide, Vial therapeutic areas include oncology , neurology , cardiology , and rare diseases.

Clinical Trials 52

Clinical Trials Trials Clinical Development Clinical Research 52

H1 Blog

JULY 30, 2024

Increasing diversity in clinical trials not only makes the findings more relevant to various patient groups, but also enhances knowledge about the disease or medical product being studied. The recent draft by the FDA introduces additional guidelines for Diversity Action Plans aimed at improving diversity in clinical research.

FDA 59

FDA Clinical Trials Compliance Pharma Companies 59

Vial

APRIL 10, 2024

The increasing costs associated with in-house drug development have prompted biotech and pharmaceutical companies to increasingly outsource to contract research organization s (CROs) for assistance. IQVIA has a vast collection of healthcare information, including over 1.2 increase on a reported basis and an 4.8%

Clinical Trials 52

Clinical Trials Trials Clinical Research Compliance 52

PPD

MAY 11, 2023

The global COVID-19 pandemic increased awareness of the importance of vaccine development — both for drug developers and the public. The speed at which COVID-19 vaccines were developed was remarkable, but like most newly developed vaccines, there was variation among who could receive the shots and when.

Vaccine 52

Vaccine Clinical Trials Long-Term Care Facilities Trials 52

H1 Blog

DECEMBER 4, 2023

As the pharmaceutical and biotech industries continue to push for faster drug development, the importance of equity and diversity in clinical trial recruitment cannot be overlooked. Let’s dive in to uncover the role of digital health and data in driving faster drug development through improved diversity.

Clinical Trials 59

Clinical Trials Trials Pharmaceutical Companies Drug Development 59

Drug Target Review

FEBRUARY 29, 2024

During my academic career, I had the opportunity to examine the underlying causes of neurodegenerative diseases like Parkinson’s disease and develop novel animal models to investigate potential disease-modifying therapeutics. For instance, we know ageing is a primary risk factor for many neurodegenerative diseases.

Therapies 111

Therapies Disease Clinical Trials Science 111

Vial

MARCH 1, 2024

Leading Global CROs To advance new therapies, pharma, biotech, and medical device sponsors engage CROs to help navigate the complex landscape of drug development and regulatory pathways and to manage clinical trials efficiently, ethically, and in compliance with good clinical practice ( GCP ) standards. billion by 2029.

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

Vial

FEBRUARY 8, 2024

To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drug development and regulatory pathways and to run clinical trials. As von Itzstein et al.

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

The Pharma Data

JANUARY 25, 2021

“The establishment of an Advisory Board focusing on Alzheimer’s disease, and the recruitment of such an impressive group of scientific and clinical leaders in this field is an extremely important step forward for the Company,” stated Paul Brennan, NervGen’s President & CEO. Dr.

Disease 40

Disease Clinical Development Molecular Biology Treatment 40

Conversations in Drug Development Trends

MARCH 20, 2024

In the increasingly advancing world of medicine, personalized care is a key factor that can progress your drug development efforts. One way to ensure customized disease management is to utilize pharmacogenomics (PGx) in your clinical trial.

Clinical Trials 52

Clinical Trials Trials Treatment Compliance 52

PPD

MARCH 21, 2024

When participating in clinical trials, pediatric populations require distinct considerations for their safety and well-being — which can present unique challenges for drug developers. A number of strategies can be adopted to put the needs of the child at the center of the study.

Clinical Trials 52

Clinical Trials Trials Drug Development Treatment 52

Conversations in Drug Development Trends

FEBRUARY 6, 2023

At Worldwide, this topic arises frequently in discussion with rare disease sponsors. As genome-wide association studies to identify genetic markers for common diseases increase, these questions will surface even more. Guidance in this area is much needed. Read the full article!

Clinical Trials 52

Clinical Trials Trials Disease Clinical Development 52

Conversations in Drug Development Trends

AUGUST 10, 2023

As one of the more recent fields to emerge in the clinical space, psychedelics have gained significant traction as a potential treatment for various neuropsychiatric diseases.

Science 98

Science Clinical Trials Trials Clinical Research 98

The Premier Consulting Blog

APRIL 18, 2024

The Cell and Gene Therapy (CGT) field has unprecedented potential to effectively treat and/or cure genetic-based rare and orphan diseases and expand the reach of personalized medicine. This blog will outline three characteristics of a successful nonclinical program to support entry into clinical trials for a cell or gene therapy product.

Therapies 52

Therapies Clinical Trials Small Molecule Immune Response 52

Crown Bioscience

MAY 4, 2021

Classified as "orphan diseases", pediatric cancers account for around 1% of all cancers in the US. In addition, owing to the rarity of these diseases, it can be extremely challenging to gain to patients and perform the clinical research necessary for regulatory approval.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

PPD

JULY 13, 2023

Their services help engage a suitable participant pool, facilitate clinical trial participation, ensure that selected sites have the resources to support clinical trial activities and more. Patient advocacy groups can create a valuable connection to potential research participants, especially for rare disease trials.

Clinical Trials 52

Clinical Trials Pharma Companies Trials Clinical Research 52

The Premier Consulting Blog

JUNE 18, 2023

This has opened new opportunities in pharmaceutical drug development, such as the ability to evaluate large complex databases and to integrate information in useful ways. One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52